FORM PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 62942-B/JPW/AJD	Serial No. 09/912,824
		Applicant(s) Graham P. Allaway et al.	
	INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Filing Date July 25, 2001	Group Art Unit 1648

U.S. PATENT DOCUMENTS

Examiner Initials	Exh. No.[§]	Document Number							Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5	4	6	4	9	6	3	11/07/95	Bolognesi et al.			
	2	5	6	0	3	9	3	3	02/18/97	Dwyer et al.			
	3	5	6	6	8	1	4	9	09/16/97	Oroszlan et al.			
	4	5	8	1	7	7	6	7	10/06/98	Allaway et al.			

FOREIGN PATENT DOCUMENTS

		Document Number							Date	Country	Class	Subclass	Translation Yes	Translation No
	42	9	2	0	1	4	5	1	02/06/92	PCT				
	43	9	6	4	1	0	2	0	12/19/96	PCT				
	44	9	7	2	6	0	0	9	07/24/97	PCT				
	45	9	7	3	7	0	0	5	10/27/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	58	Allaway, G.P. et al. (1995) Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 11: 533-539;
	59	Allaway, G.P. et al. (1993) Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res. Hum. Retroviruses 9: 581-587;
	60	Allaway, G.P. et al. (1993) Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. J. Cell. Biochem. 17E: 25, see abstract;
	61	Amara, A. et al. (1997) HIV coreceptor downregulation as antiviral principle: SDF-1a-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J. Exp. Med. 186: 139-146;
	62	Arthos, J. et al. (1989) Identification of the residues in human CD4 critical for the binding of HIV. Cell 57: 469-481;
	63	Berger, E.A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11 (suppl A): S3-S16;
	64	Bieniasz, P.D. et al. (1997) HIV-1 induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR5 co-receptor. EMBO J. 16: 2599-2609;

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

§ Note that this column shows Exhibit numbers, not reference numbers. Reference numbers are listed on pages 14-31 of the attached Amendment.

10/25/2004 RFEKADU1 00000144 09912824
04 FC:1806 180.00 OP